Hirofumi TADA Attorney-at-law |
||||||
|
||||||
EDUCATION /WORK EXPERIENCE |
||||||
WORK EXPERIENCE |
||||||
|
||||||
EDUCATION |
||||||
|
||||||
PUBLICATIONS |
||||||
◆The Patent Litigation Review 2025:Japan(IAM)(2024) ◆Life Sciences & Pharma IP Litigation(Chambers)(2023-2024) ◆Asia-Pacific Patent Litigation Review(IAM)(2024) ◆Dwango Intellectual Property High Court En Banc Decision on the Territoriality of Japanese Patent (Korea Institute of Intellectual Property) ◆Global Patent Litigation: Japan (IAM) (2022) ◆A comparison of patent regimes: Japan (Asia Business Law Journal) (2022) ◆Secondary Considerations of U.S. Nonobviousness (Chizai Prism) (2022.10) ◆Risk of U.S. Declaratory Judgment (Chizai Prism) (2022.9) ◆Patent Marking (Chizai Prism) (2022.8) ◆Pro-Patent Trend of Infringement Lawsuits in Japan (Chizai Prism) (2022.7) ◆Joint Inventorship & Ownership of U.S. Patent Rights (Chizai Prism) (2022.6) ◆Divided Infringement of U.S. Patents (Chizai Prism) (2022.5) ◆Territorial Scope of U.S. Patent Rights (Chizai Prism) (2022.3) ◆Patent law development in Japan (Asia Business Law Journal) (2021) ◆Updates on trademark law in Japan (Asia Business Law Journal) (2021) ◆Recent Trend of Pharmaceutical Patent Litigation (Legal Mind) (2020) |
||||||
ACTIVITIES |
||||||
◆2016- Research Fellow of Intellectual Property Research Division of
|
||||||
PRESENTATIONS |
||||||
◆"Patentability of antibody inventions in Japan and the United States" (Japan Pharmaceutical Industry Legal Affairs Association, 2023) ◆“Patents & Disputes of Genome Technologies” (JETRO New York, 2022) ◆“Artificial Intelligence & IP: Patent Race, Patent Eligibility, and Other Issues”(Taiwan Patent Attorneys Association, 2022) ◆"Artificial Intelligence & IP: Eligibility, Ownership, and Enforcement" (AIPPI JAPAN, 2022) |
||||||
LANGUAGES |
||||||
Japanese, English | ||||||